author-photo

James Edward Shaw

Virginia Commonwealth University

21

Papers

786

Citations

Citation Trend

Filter By

Papers (15) Sort By

Journal Conference Others

Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405

2020 JNCI Cancer Spectrum
Show All
- Source
- Cite
- Save
Citations (2)
Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Innovation, education, and research: A multidisciplinary survivorship care model.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 3285: Body mass index, weight loss, and progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance)

2019 Epidemiology
Show All
- Source
- Cite
- Save
Citations (0)
Association of RAS mutations with race in metastatic colorectal cancer: CALGB/SWOG 80405 (ALLIANCE).

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Celiac plexus block in patients with nonpancreatic GI malignancies: Experience from a single institution.

2017 Journal of Clinical Oncology
- Shejal B Patel
- James Edward Shaw
Show All
- Source
- Cite
- Save
Citations (0)
Impact of primary (1º) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (218)
Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (13)
O-0019CALGB/SWOG 80405: PHASE III TRIAL OF IRINOTECAN/5-FU/LEUCOVORIN (FOLFIRI) OR OXALIPLATIN/5-FU/LEUCOVORIN (MFOLFOX6) WITH BEVACIZUMAB (BV) OR CETUXIMAB (CET) FOR PATIENTS (PTS) WITH KRAS WILD-TYPE (WT) UNTREATED METASTATIC ADENOCARCINOMA OF THE COLON

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (32)
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (365)